Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Effects of Selonsertib in Patients with Diabetic Kidney Disease.

Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD; GS-US-223-1015 Investigators; Pergola.

J Am Soc Nephrol. 2019 Sep 10. pii: ASN.2018121231. doi: 10.1681/ASN.2018121231. [Epub ahead of print]

PMID:
31506292
2.

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T.

JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055.

PMID:
31334793
3.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

4.

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Poe JC, Jia W, Di Paolo JA, Reyes NJ, Kim JY, Su H, Sundy JS, Cardones AR, Perez VL, Chen BJ, Chao NJ, Cardona DM, Saban DR, Sarantopoulos S.

JCI Insight. 2018 Oct 4;3(19). pii: 122430. doi: 10.1172/jci.insight.122430.

5.

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.

Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA.

Eur Respir J. 2018 Sep 17;52(3). pii: 1801384. doi: 10.1183/13993003.01384-2018. Print 2018 Sep.

PMID:
30139770
6.

A phase 2, Randomized, Placebo-controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients with Moderately to Severely Active Crohn's Disease.

Schreiber S, Siegel CA, Friedenberg KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundy JS, Lee SD, Loftus EV Jr.

J Crohns Colitis. 2018 May 29. doi: 10.1093/ecco-jcc/jjy070. [Epub ahead of print]

7.

Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S.

J Crohns Colitis. 2018 May 14. doi: 10.1093/ecco-jcc/jjy049. [Epub ahead of print]

8.

Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis.

Gossage DL, Cieslarová B, Ap S, Zheng H, Xin Y, Lal P, Chen G, Smith V, Sundy JS.

Clin Ther. 2018 Jan;40(1):156-165.e5. doi: 10.1016/j.clinthera.2017.11.011. Epub 2017 Dec 26.

PMID:
29287749
9.

The cortisol:C-reactive protein ratio and negative affect reactivity in depressed adults.

Suarez EC, Sundy JS.

Health Psychol. 2017 Sep;36(9):852-862. doi: 10.1037/hea0000517. Epub 2017 Jun 26.

10.

Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases.

Patel DD, Antoni C, Freedman SJ, Levesque MC, Sundy JS.

J Allergy Clin Immunol. 2017 Sep;140(3):685-687. doi: 10.1016/j.jaci.2017.04.029. Epub 2017 May 12. No abstract available.

PMID:
28506849
11.

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.

Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C; RDEA594-203 Study Group.

Ann Rheum Dis. 2016 Jun;75(6):1074-80. doi: 10.1136/annrheumdis-2015-207919. Epub 2016 Jan 7.

12.

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ.

Ann Rheum Dis. 2015 Oct;74(10):1789-98. doi: 10.1136/annrheumdis-2015-208237. Erratum in: Ann Rheum Dis. 2016 Feb;75(2):473.

13.

2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vazquez-Mellado J, Yarows SA, Taylor WJ.

Arthritis Rheumatol. 2015 Oct;67(10):2557-68. doi: 10.1002/art.39254. Erratum in: Arthritis Rheumatol. 2016 Feb;68(2):515. Vaquez-Mellado, Janitzia [corrected to Vazquez-Mellado, Janitzia].

14.

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.

Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA.

J Clin Rheumatol. 2014 Dec;20(8):427-32. doi: 10.1097/RHU.0000000000000200. Review.

15.
16.

Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.

Sundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King-Davis S, Evans RR.

J Rheumatol. 2014 Aug;41(8):1703-11. doi: 10.3899/jrheum.131226. Epub 2014 Jul 15.

PMID:
25028379
17.

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.

Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS.

Arthritis Res Ther. 2014 Mar 7;16(2):R63. doi: 10.1186/ar4500.

18.

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA.

Arthritis Res Ther. 2014 Mar 4;16(2):R60. doi: 10.1186/ar4497.

19.

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA.

Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318.

20.

Using registries to identify adverse events in rheumatic diseases.

Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.

Pediatrics. 2013 Nov;132(5):e1384-94. doi: 10.1542/peds.2013-0755. Epub 2013 Oct 21. Review.

21.

Racial differences in the association of CD14 polymorphisms with serum total IgE levels and allergen skin test reactivity.

Wang Z, Sundy JS, Foss CM, Barnhart HX, Palmer SM, Allgood SD, Trudeau E, Alexander KM, Levesque MC.

J Asthma Allergy. 2013 Jun 25;6:81-92. doi: 10.2147/JAA.S42695. Print 2013.

22.

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS.

Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795. Epub 2012 Nov 10.

23.

The rheumatology of gout.

Sundy JS.

Adv Chronic Kidney Dis. 2012 Nov;19(6):404-12. doi: 10.1053/j.ackd.2012.07.012. Review. Erratum in: Adv Chronic Kidney Dis. 2013 Jan;20(1):110. Dosage error in article text.

PMID:
23089276
24.

Pegloticase for treating refractory chronic gout.

George RL Jr, Sundy JS.

Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475. Review.

PMID:
22844655
25.

The clinical and environmental determinants of airway transcriptional profiles in allergic asthma.

Yang IV, Tomfohr J, Singh J, Foss CM, Marshall HE, Que LG, McElvania-Tekippe E, Florence S, Sundy JS, Schwartz DA.

Am J Respir Crit Care Med. 2012 Mar 15;185(6):620-7. doi: 10.1164/rccm.201108-1503OC. Epub 2012 Jan 12.

26.

Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.

Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, Yancopoulos GD, Soo Y, King-Davis S, Weinstein SP, Radin AR; 0619 Study Group.

Arthritis Rheum. 2012 Mar;64(3):876-84. doi: 10.1002/art.33412.

27.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
28.

Pulmonary function, bronchial reactivity, and epithelial permeability are response phenotypes to ozone and develop differentially in healthy humans.

Que LG, Stiles JV, Sundy JS, Foster WM.

J Appl Physiol (1985). 2011 Sep;111(3):679-87. doi: 10.1152/japplphysiol.00337.2011. Epub 2011 Jun 23.

29.

Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.

Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA.

J Med Econ. 2011;14(1):10-5. doi: 10.3111/13696998.2010.540874. Epub 2010 Dec 7.

PMID:
21138339
30.

Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.

Hershfield MS, Roberts LJ 2nd, Ganson NJ, Kelly SJ, Santisteban I, Scarlett E, Jaggers D, Sundy JS.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14351-6. doi: 10.1073/pnas.1001072107. Epub 2010 Jul 26.

31.

Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.

Mandell BF, Edwards NL, Sundy JS, Simkin PA, Pile JC.

Cleve Clin J Med. 2010 Jun;77 Suppl 2:S2-25. doi: 10.3949/ccjm.77.s2.01. No abstract available.

PMID:
20516241
32.

Progress in the pharmacotherapy of gout.

Sundy JS.

Curr Opin Rheumatol. 2010 Mar;22(2):188-93. doi: 10.1097/BOR.0b013e3283369014. Review.

PMID:
20110792
33.

A natural experiment in the quality of care in gout.

Sundy JS.

Curr Opin Rheumatol. 2010 Mar;22(2):164. doi: 10.1097/BOR.0b013e3283368fca. No abstract available.

PMID:
20110791
34.

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A.

Ann Rheum Dis. 2009 Oct;68(10):1613-7. doi: 10.1136/ard.2009.108936. Epub 2009 Jul 26.

35.

Quality of life and disability in patients with treatment-failure gout.

Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, Maroli A, Huang B; Gout Natural History Study Group, Sundy JS.

J Rheumatol. 2009 May;36(5):1041-8. doi: 10.3899/jrheum.071229. Epub 2009 Mar 30.

PMID:
19332629
36.

Gout management: let's get it right this time.

Sundy JS.

Arthritis Rheum. 2008 Nov 15;59(11):1535-7. doi: 10.1002/art.24201. No abstract available.

37.

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study Investigators.

Arthritis Rheum. 2008 Sep;58(9):2882-91. doi: 10.1002/art.23810.

38.

Normative values for exhaled breath condensate pH and its relationship to exhaled nitric oxide in healthy African Americans.

Hauswirth DW, Sundy JS, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, Allgood S, McNair PD, Levesque MC.

J Allergy Clin Immunol. 2008 Jul;122(1):101-6. doi: 10.1016/j.jaci.2008.03.024. Epub 2008 May 12.

PMID:
18472151
39.

Refractory gout: what is it and what to do about it?

Fels E, Sundy JS.

Curr Opin Rheumatol. 2008 Mar;20(2):198-202. doi: 10.1097/BOR.0b013e3282f4eff5. Review.

PMID:
18349751
40.

Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults.

Levesque MC, Hauswirth DW, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, Allgood S, McNair PD, Allen AS, Sundy JS.

J Allergy Clin Immunol. 2008 Feb;121(2):396-402.e3. Epub 2007 Nov 26.

PMID:
18036642
41.

Smoking is associated with an age-related decline in exhaled nitric oxide.

Sundy JS, Hauswirth DW, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, Allgood S, McNair PD, Levesque MC.

Eur Respir J. 2007 Dec;30(6):1074-81. Epub 2007 Oct 10. Erratum in: Eur Respir J. 2008 Apr;31(4):911.

42.

Uricase and other novel agents for the management of patients with treatment-failure gout.

Sundy JS, Hershfield MS.

Curr Rheumatol Rep. 2007 Jun;9(3):258-64. Review.

PMID:
17531181
43.

Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS.

Arthritis Rheum. 2007 Mar;56(3):1021-8. Erratum in: Arthritis Rheum. 2007 Apr;56(4):1370.

44.

Safety of incremental inhaled lipopolysaccharide challenge in humans.

Sundy JS, Wood WA, Watt JL, Kline JN, Schwartz DA.

J Endotoxin Res. 2006;12(2):113-9.

PMID:
16690014
45.

Update on nonsteriodal anti-inflammatory drugs.

Ardoin SP, Sundy JS.

Curr Opin Rheumatol. 2006 May;18(3):221-6. Review.

PMID:
16582683
47.

Symptomatic effects of exposure to diluted air sampled from a swine confinement atmosphere on healthy human subjects.

Schiffman SS, Studwell CE, Landerman LR, Berman K, Sundy JS.

Environ Health Perspect. 2005 May;113(5):567-76.

48.

Bioaerosols and innate immune responses in airway diseases.

Hauswirth DW, Sundy JS.

Curr Opin Allergy Clin Immunol. 2004 Oct;4(5):361-6. Review.

PMID:
15349034
49.

Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey.

Law AW, Reed SD, Sundy JS, Schulman KA.

J Allergy Clin Immunol. 2003 Feb;111(2):296-300.

PMID:
12589348
50.

COX-2 inhibitors in rheumatoid arthritis.

Sundy JS.

Curr Rheumatol Rep. 2001 Feb;3(1):86-91. Review.

PMID:
11177775

Supplemental Content

Loading ...
Support Center